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Abstract
New therapeutic strategies are needed to improve treatment for head and neck squamous cell
carcinoma (HNSCC), an aggressive tumor with poor survival rates. FRMD4A is a human
epidermal stem cell marker implicated previously in epithelial polarity that is upregulated in SCC
cells. Here we report that FRMD4A upregulation occurs in primary human HNSCC where high
expression levels correlate with increased risks of relapse. FRMD4A silencing decreased growth
and metastasis of human SCC xenografts in skin and tongue, reduced SCC proliferation and
intercellular adhesion, and stimulated caspase-3 activity and expression of terminal differentiation
markers. Notably, FRMD4A attenuation caused nuclear accumulation of YAP, suggesting a
potential role for FRMD4A in Hippo signaling. Treatment with the HSP90 inhibitor 17-DMAG or
ligation of CD44 with hyaluronan caused nuclear depletion of FRMD4A, nuclear accumulation of
YAP and reduced SCC growth and metastasis. Together, our findings suggest FRMD4A as a
novel candidate therapeutic target in HNSCC based on the key role in metastatic growth we have
identified.
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Introduction
Squamous cell carcinoma (SCC) of the skin and oral cavity pose differing threats to health.
Skin SCCs are very common and rarely metastasise; they can often be cured by surgery
alone (1). SCCs in the oral cavity (head and neck SCC; HNSCC) are less common, but tend
to present at an advanced stage (2). Despite radical surgery and adjuvant therapy, HNSCC
lesions often recur and spread to other body sites. Survival rates for oral SCC are
approximately 50% and have not improved for 30 years.
Both skin SCC and HNSCC arise from multi-layered epithelia, which are maintained by
stem cells residing in the basal epithelial layer, attached to an underlying basement
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membrane (3). Skin SCC and HNSCC exhibit cellular heterogeneity, with some cells
expressing markers of the normal terminal differentiation process while others are
undifferentiated. There is also good evidence for functional heterogeneity, both in terms of
clonal growth of SCC cells in vitro (4, 5) and in xenografts in immune compromised mice
(6). Thus, SCC is one of the tumour types for which there is experimental support for the
existence of cancer stem cells (tumour initiating cells) (7).
Using single cell gene expression profiling, we identified FERM domain containing 4A
(FRMD4A) mRNA as a marker of cultured human epidermal stem cells (8). When we
examined expression of a panel of 14 epidermal stem cell markers in cultured HNSCC cells,
FRMD4A was the only marker that was consistently highly upregulated in HNSCC and thus
emerged as a candidate HNSCC stem cell marker (5). FRMD4A was recently reported to
connect the Par-3 complex to Arf6 guanine-nucleotide exchange factor and regulate
assembly of adherens junctions in cultured mammary epithelial cells (9).
We have now characterised FRMD4A expression and function in SCC and present evidence
that it is an attractive target for novel therapies to control SCC growth and metastasis.
Materials and Methods
Analysis of FRMD4A levels in published datasets
Processed gene expression data from two published HNSCC studies (10, 11) were
downloaded from NCBI GEO (Accession numbers GSE10300 and GSE686). The X-Tile
program (12) was used to determine the optimal cut-point for Kaplan Meier analysis
performed using the ‘survival’ package for R, while correcting for the use of minimum P
statistics.
Human tissue specimens
Work with human material was carried out in compliance with the UK Human Tissue Act
(2004) and approved by the National Research Ethics Service (08/H0306/30). Appropriate
informed consent was obtained from patients diagnosed with oral SCC, prior to operation at
Addenbrooke’s Hospital. Small biopsy specimens were removed from freshly resected oral
SCCs. Specimens of normal skin were obtained with informed consent from operations to
remove excess skin.
For laser capture microdissection, tissue was frozen in OCT and sectioned with a cryostat.
Sections were briefly air-dried and stained with cresyl violet. Using the Zeiss/P.A.L.M.
Laser Capture Microdissection system the basal and granular epidermal layers were
collected separately from two serial sections and material from both sections was pooled.
RNA was isolated using RNeasy (Quiagen), then reverse transcribed with an Superscript III
kit (Invitrogen).
Cell culture and lentiviral transduction
SCC13 and SCC25 (13) and keratinocytes from normal human epidermis (ky passage 4) and
oral mucosa (CRI-005 passage 4) were cultured as described previously (5, 8), except that
SCC lines were grown without a feeder layer of J2 3T3 cells. SCC13 and SCC25 cells were
passaged for less than 6 months following thawing. SCC25 are available from ATCC
(Manassas, Virginia) and validated by short tandem repeat profiling. The culture medium
comprised FAD (three parts DMEM medium, one part Ham’s F12 medium, 1.8 × 10−4M
adenine) supplemented with 10% FCS, 0.5μg/ml hydrocortisone, 5μg/ml insulin, 10−10M
cholera toxin and 10ng/ml epidermal growth factor. SJG15 cells were derived from a SCC
(pathological stage T2N1M0; well differentiated) on the lateral tongue of a 51-year old
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female patient. Cells from the tumour were disaggregated in 0.25% trypsin/EDTA (Gibco)
at 37°C then passaged on feeders until they became feeder-independent.
The YFP/Luciferase lentivirus construct was generated in-house. shRNA constructs were
purchased from Open Biosystems. Viruses were packaged by transient transfection of 293T
cells (14, 15). Viral supernatant was used to infect SCC cells. Infected cells were selected in
hygromycin (YFP/Luciferase) or puromycin (shRNAs).
To stimulate keratinocyte differentiation, cells were grown in Keratinocyte Serum Free
Medium (KSFM, Gibco) supplemented with 30 μg/ml Bovine Pituitary Extract and 0.2 ng/
ml EGF for 2-3 days. Cells were then incubated in medium containing 10 μM AG1478
(Calbiochem) and/or 200 ng/ml recombinant human BMP2/7 heterodimer (R&D systems)
for 48h.
For colony forming assays, 100 cells were plated in triplicate in 10cm plates without
feeders. After 14 days, cultures were fixed and stained with 1% Rhodamine B and 1% Nile
blue (Acros Organic). Colony-forming efficiency was calculated as the percentage of plated
cells that formed a colony of three or more cells.
For real time imaging, 1000 cells were plated, in triplicate for each condition, in a 48-well
plate without feeders and recorded using an Incucyte. Wells were imaged every 3 hours for
7 days.
Matrigel invasion assays were carried out using Boyden chambers (BD BioCoat™
Matrigel™ Invasion Chambers) in 24-well plates. Cells transduced with YFP/luciferase
were serum starved in KSFM for 24 hours. 105 cells in KFSM were added per chamber in
wells containing complete FAD medium. After 24 hours the Matrigel was removed from the
well, and luciferin was added to the medium. The chambers were scanned and quantified
using the IVIS.
For sphere forming assays, a 12-well plate was coated with polyHEMA to prevent adhesion
of cells to the plastic. 100 cells were plated in methylcellulose in each well, in triplicate.
After 21 days the wells were scanned and quantified using a Typhoon scanner.
Q-PCR
RNA was isolated and amplified as described previously (8). Q-PCR was performed using
Taqman Gene Expression Assays for FRMD4A and transglutaminase (Applied Biosystems).
All data were normalised to 18S.
Antibodies
SGO-3 and SGO-4 antibodies were raised by injecting FRMD4A peptide
PPPQSLEGLRQMHYHRNDYDKC into rabbits. The antibodies were affinity purified on
AminoLink® Plus Coupling Resin columns (Thermo scientific). The following antibodies
were also used: α6 integrin (GoH3; BD Pharmigen, Oxford, UK), E-cadherin (HECD-1)
(prepared in-house), GFP (Abcam, Cambridge, UK), Ki67 (Dako, UK), cleaved caspase-3
(R&D Systems, UK), YAP1 (Abcam), LATS1 (Abcam), MST1 (Abcam), Involucrin (SY3;
prepared in-house), CD44 (BD Pharmigen, Oxford, UK), and GAPDH (Invitrogen).
AlexaFluor-488 or -555 conjugated secondary antibodies and HRP conjugated secondary
antibodies were purchased from Invitrogen.
Histology and in situ hybridisation
Tissue was either fixed in 10% neutral-buffered formalin and embedded in paraffin, or
frozen in OCT embedding matrix (Raymond A. Lamb, UK). Epitope retrieval was
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performed on paraffin sections by boiling in citrate buffer for 10 minutes. Blocking buffer
contained 10% fetal calf serum, 4% bovine serum, 2.5% fish skin gelatin and 0.05% Tween
20. Staining was performed essentially as described previously (16). Immunofluorescence
staining was imaged using a Leica Tandem Confocal microscope. Ki67 stained sections
were photographed and analyzed using an Ariol SL-50 system (Applied Imaging, Corp.), as
described previously (16). In situ hybridization was performed on sections of paraffin-fixed
human foreskin, essentially as described previously (17).
Western blotting
Cells were disaggregated using trypsin/EDTA and collected by centrifugation. Cell pellets
were lysed in RIPA buffer containing protease and phosphatase inhibitors (16) and subjected
to polyacrylamide gel electrophoresis on 4% to 12% gradient gels. Proteins were transferred
to nitrocellulose membranes and blocked in Tris buffer pH 8.0 containing 2.5% skimmed
milk powder and 0.05% Tween 20. Blots were incubated with primary and secondary
antibodies and visualised by enhanced chemiluminescence (16). Antibodies to FRMD4A
and YAP were used at 1:200 dilution; anti-GAPDH was diluted 1:1000.
Xenografts
Experiments were subject to Cancer Research UK ethical review and performed under the
terms of a U.K. Government Home Office license. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mice were purchased from the Jackson Laboratories (Maine, USA) and bred in-
house. Mice were subject to inhalation anaesthesia during SCC implantation and IVIS
imaging.
SCC cells were introduced into the anterior dorsal mucosa of the tongue with a 30g needle
and 1ml syringe. For tail vein injections 2.5 × 105 cells in 50μl culture medium were
introduced per mouse. To form tumours in back skin, silicone chambers were first implanted
into a full thickness wound, as described previously (18). SCC cells were injected into the
chamber and one week later the top of the chamber was cut off. After a further week the
whole silicone chamber was removed.
Tumour size was determined by scanning mice in an IVIS 200 series imaging system
(Caliper LifeSciences) following intraperitoneal injection of 15mg/ml D-Luciferin
(potassium salt) dissolved in PBS (10μl/g). Tumour size was recorded weekly. To induce
FRMD4A knockdown with doxycycline, mice were fed chow containing the drug (IPS
Product Supplies UK).
To evaluate the effect of HA treatment, 106 SCC13 cells were implanted into the back skin.
One week later tumour size was measured using the Xenogen IVIS and then each tumour
was injected with 200μl of 0.1% HA (Sigma) or 200μl PBS alone.
To evaluate the effect of 17-DMAG treatment, 105 SCC25 cells were injected into the
tongue. One week later tumour size was measured using the Xenogen IVIS and then each
mouse received an intraperitoneal injection of 17-DMAG or vehicle control. Mice were
subsequently injected once a week. For the first five weeks mice received 0.02mg 17-
DMAG (Tocris). Thereafter the weekly dose was 0.04mg. A stock solution of 17-DMAG
was prepared in 100% ethanol and diluted in PBS prior to injection. Control mice received
injections of PBS alone.
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Results
FRMD4A is expressed in the basal layer of human epidermis and is upregulated in HNSCC
To determine where FRMD4A (genome accession number NM_018027) is expressed in
normal human epidermis we performed in situ hybridisation with a 35S labelled probe to
exon 25 (Figure 1A). FRMD4A transcripts were detected throughout the basal layer, where
the stem cells reside (3, 8), but there was no signal above background in the suprabasal,
differentiating cell layers. Hybridisation with a βa-actin probe provided a positive control as
β-actin is expressed in all epidermal cell layers (Figure 1A).
Our observations were confirmed by q-PCR of mRNA isolated from the basal and upper
differentiated (granular) layers of human epidermis following laser capture microdissection.
The differentiation marker transglutaminase 1 was highly expressed in the granular layer
and absent from the basal layer, whereas FRMD4A was upregulated in the basal layer and
undetectable in the granular layer (Figure 1B). An inverse correlation between levels of
FRMD4A and transglutaminase 1 was also observed in cultured human keratinocytes:
addition of BMP2/7 and/or the EGF receptor antagonist AG1478 stimulated
transglutaminase 1 expression and led to a corresponding decrease in FRMD4A (Figure 1B).
We conclude that, as predicted for an epidermal stem cell marker (8), FRMD4A mRNA is
expressed in basal layer keratinocytes and downregulated during terminal differentiation.
In addition to the FERM domain, FRMD4A is predicted (by motif scan analysis; 19) to have
a coiled-coil domain, a bipartite nuclear localisation signal (NLS), a serine-rich C-terminal
domain and numerous potential serine, threonine and tyrosine phosphorylation sites (Figure
1C and data not shown). In order to detect FRMD4A protein we raised rabbit antisera
(SGO-3, 4) to a peptide that lies between the NLS and the serine-rich domain (Figure 1C).
Both antibodies recognised a single band of approximately 76kD in Western blots of
cultured human keratinocytes and SCC cells (SCC13, derived from a facial epidermal SCC;
13), somewhat smaller than the predicted size of 115 kDa (Figure 1C and data not shown).
To evaluate antibody specificity, SCC13 cells were transduced with 5 different lentiviral
shRNAs to FRMD4A or a scrambled shRNA control (SCR) (Figure 1C). All but one of the
shRNAs (A9) caused a marked reduction in the abundance of the protein band detected by
SGO-3 and SGO-4 (Figure 1C). As predicted from FRMD4A mRNA levels (5), the level of
FRMD4A protein was higher in SCC13 than in primary keratinocytes cultured from
epidermis (EK) or oral cavity (OK) (Figure 1C).
SGO-3 and SGO-4 were used to examine FRMD4A protein expression in sections of normal
human skin and HNSCC. As predicted from the in situ hybridisation and q-PCR data,
FRMD4A was expressed in the epidermal basal layer and downregulated in the suprabasal
layers (Figure 1C). We next stained 13 tumours of the alveolar ridge, tongue and floor of
mouth (6 well differentiated; 4 moderately differentiated; 3 poorly differentiated). FRMD4A
protein was expressed throughout the epithelial compartment of human HNSCC and was
upregulated regardless of pathological grade (Figure 1C).
To further evaluate the significance of FRMD4A upregulation in HNSCC, we examined
published gene expression data from two collections of tumours (10, 11) using the X-Tile
program (12). Kaplan Meier plots from both datasets showed a highly significant correlation
between high levels of FRMD4A and risk of relapse (Figure 1D).
We conclude that in normal epidermis FRMD4A expression is confined to the basal layer,
where the stem cells reside; that FRMD4A is widely expressed throughout the tumour mass
in HNSCC; and that high FRMD4A levels are correlated with poor prognosis in HNSCC.
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FRMD4A knockdown reduces cell-cell adhesion, growth and invasion in culture
We used SCC13 cells and a second human SCC line, SCC25 (derived from a tongue SCC;
13), to examine the consequences of reduced FRMD4A expression on SCC cell behaviour in
vitro. In untransduced SCC13 (SCC13-WT) and SCC13 transduced with a scrambled
shRNA control (SCC13-SCR) FRMD4A was located predominantly in the cytoplasm, with
some localisation to the nucleus and partial colocalisation with E-cadherin at cell-cell
borders (Figure 2A). FRMD4A knockdown (SCC13-A7) led to loss of FRMD4A in all
locations and to a marked reduction in E-cadherin staining, which coincided with reduced
cell-cell contact and elongated cell morphology (Figure 2A). Live cell imaging confirmed
that whereas SCC13-WT and SCC13-SCR cells formed colonies with stable intercellular
adhesions, SCC13-A7 cells did not (Supplemental Figure 1).
FRMD4A knockdown in SCC13 and SCC25 using several different shRNAs resulted in a
reduction in colony forming efficiency, a surrogate readout of stem cell abundance (5)
(Figure 2B). The reduction in colony formation correlated with an overall reduction in
growth rate, as evaluated by live cell imaging (Supplemental Figure 1; Figure 2C). In
addition, FRMD4A knockdown led to reduced SCC invasiveness in Boyden chamber assays
and inhibition of anchorage dependent growth, as determined by sphere formation in
suspension (Figure 2D).
Generation of an orthotopic xenograft model of human HNSCC
In HNSCC, death is frequently due to organ failure as a result of distant metastasis, rather
than growth of the primary tumour (2). However, HNSCC growth in xenograft models is
generally evaluated by the size of the primary tumour generated by grafting cells in a
heterotopic site, the dorsal skin (6). To generate an improved xenograft model we
transduced cultured SCC cells with a lentiviral construct that expressed a YFP/luciferase
fusion protein so that tumour growth could be evaluated both macroscopically and
microscopically (Figure 3A). Cells were either injected into a silicone chamber surgically
implanted in the back skin (18) or directly injected into the tongue of NSG mice (Figure
3B). Primary tumours were evaluated in live mice using an IVIS 200 series imaging system
(Caliper LifeSciences) following intraperitoneal injection of luciferin (Figure 3B). Organs
were scanned post-mortem with an IVIS to detect metastatic disease (Figure 3B).
The tumorigenicity of SCCs depended on the location of the graft: chamber grafted SCCs
required a minimum of 104 cells in order to successfully form a tumour in 100% of mice,
whereas tongue grafted tumours developed after injection of only 100 cells (based on
cohorts of 5 mice per group). The average survival times for mice injected with 104 SCC13
in the dorsal skin (73d) or 100 SCC13 cells (70d) in the tongue were similar, although the
maximum survival time was greater in the tongue (135d versus 76d). In contrast, both the
average (90d versus 61d) and maximum survival times (157d versus 73d) of SCC25 were
greater in skin than in tongue. Thus each SCC line was more malignant when grafted into
the location from which it was derived.
Histological analysis of skin xenografts revealed growth of the tumour throughout the host
dermis and invasion of the panniculus carnosus muscle, with ulceration of the overlying skin
(Figure 3C). Oral SCCs often present as an ulcerating lesion on the tongue and this was
recapitulated in the orthotopic tongue xenografts (arrow, Figure 3C). There was extensive
infiltration into the musculature of the tongue. Although SCC13 and SCC25 originated in
different body sites, they presented similar histology in tongue and back xenografts (Figure
3C and data not shown).
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Stable knockdown of FRMD4A reduces the growth rate of human SCCs and increases host
survival
To evaluate the effect of FRMD4A knockdown on tumour growth we used two independent
strategies, one involving a conventional shRNA approach and the other involving an
inducible vector (Figure 4). We compared the effects on SCC13 and SCC25 cells growing in
back skin or tongue. All cells were transduced with the luciferase/YFP construct shown in
Figure 3A so that tumour growth could be measured in living mice.
We first evaluated the growth as tongue xenografts of control SCC25 (SCC25-WT), SCC25
transduced with a scrambled shRNA (SCC25-SCR) and SCC25 in which FRMD4A had
been knocked down (SCC25-A7). SCC25 cells were compared with SCC13 and SJG15
(recently derived from an aggressive tongue SCC) (Figure 4A). 104 cells were injected into
25 mice (n=5 per cell type) and primary tumour growth was evaluated by luciferase activity
at intervals. SCC13, SJG-15, SCC25-SCR and SCC25-WT grew at a similar rate and mice
had to be sacrificed between days 45 and 135 because their weight had dropped by 20% or
their general condition had deteriorated (Figure 4A). In contrast, growth of SCC25-A7
tumours levelled off after approximately 3 weeks and mice showed excellent long-term
survival (Figure 4A). Stable knockdown of FRMD4A increased the minimum number of
SCC25 cells required to form a tongue tumour from 100 to 104.
To evaluate the effect of FRMD4A knockdown in established tumours, SCC13 cells were
infected with a Tet-on doxyxcycline inducible FRMD4A shRNA or the empty vector control
(EV), and then injected into chamber grafts on the back of NSG mice. Three weeks later
mice were given doxyxcycline-rich chow to induce FRMD4A knockdown. Prior to the
change of diet, SCC13-EV and SCC13-FRMD4A tumours were increasing in size (Figure
4B). However, on addition of doxyxcycline SCC13-FRMD4A tumours grew significantly
more slowly (Figure 4B). Survival was significantly longer in mice in which FRMD4A had
been knocked down than in control mice (Figure 4B).
We also evaluated the effect of stable FRMD4A knockdown on SCC13 following injection
into the tail vein of NSG mice (Figure 4C). As expected, primary tumours developed in the
lungs. Mice were sacrificed after 10 days and their lungs scanned. As in the case of skin and
tongue tumours, FRMD4A knockdown reduced tumour growth.
To evaluate whether FRMD4A knockdown affected metastasis as well as primary tumour
growth, organs from each mouse in the experiments shown in Figure 4B were scanned in an
IVIS immediately post-mortem. Lungs and liver were selected for quantification, as they are
the distant organs most affected by metastases in the human disease (2). In both organs,
greater levels of metastatic disease were found in mice engrafted with SCC13 expressing the
empty vector control than mice in which FRMD4A was knocked down (Figure 4D). In
doxycycline-treated mice injected with SCC13-EV, 5/5 had lung and 4/5 had liver
metastases, whereas in mice injected with SCC13-FRMD4A 1/5 had lung and 2/5 had liver
metastases.
FRMD4A knockdown reduces proliferation, stimulates differentiation and induces
apoptosis of SCC cells
The xenograft experiments show that knockdown of FRMD4A decreased tumour growth
and metastasis. To investigate the underlying mechanisms, histological sections of primary
and secondary tumours from the experiment shown in Figure 4B were examined (Figure 5).
FRMD4A knockdown tumours showed a decrease in proliferative, Ki67 positive, cells
(Figure 5A) and exhibited extensive expression of the apoptosis marker cleaved caspase-3,
which was not detected in control tumours (Figure 5B). This correlated with an increase in
differentiation, as evaluated both by conventional histology (Figure 5A and data not shown)
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and by increased expression of the terminal differentiation marker involucrin (Figure 5C).
As predicted from the in vitro experiments (Figure 2), E-cadherin levels were reduced in
FRMD4A knockdown tumours (Figure 5D). Labelling with SGO-3 confirmed successful
knockdown of FRMD4A in tumours (Figure 5D).
We conclude that the reduced growth of tumours in which FRMD4A is knocked down
reflects a reduction in proliferation, increased apoptosis and differentiation, and a decrease
in levels of E-cadherin.
FRMD4A influences SCC growth by modulating the Hippo pathway
FERM domain containing proteins of the ezrin/radixin/moesin (ERM) subfamily lie
downstream of receptors that mediate cell-cell and cell-extracellular matrix adhesion,
including CD44, and regulate the mammalian Hippo signalling pathway (20, 21, 22, 23).
Given the effects of FRMD4A on E-cadherin levels in cultured cells and tumours, we
investigated whether FRMD4A regulates Hippo signalling. The primary effector of the
Hippo pathway is the transcriptional co-activator YAP. Phosphorylation of YAP by
LATS1/2 maintains YAP in the cytoplasm, whereas removal of LATS1/2 allows
unphosphorylated YAP to enter the nucleus and associate with DNA-binding transcription
factors of the TEAD/TEF family. LATS1/2 is activated through phosphorylation by a
complex containing the mammalian Hippo homologues MST1 and 2 (21).
Cultured SCC13-WT, SCC13-SCR and SCC13-A7 were stained for YAP1, LATS1 and
MST1 (Figure 6A and data not shown). SCC13-WT and SCC13-SCR cells showed
generalised cytoplasmic staining for YAP, with minimal nuclear accumulation (Figure 6A).
In contrast, on knockdown of FRMD4A YAP had a predominantly nuclear localisation
(Figure 6A). FRMD4A knockdown had little effect on MST localisation, but staining of
LATS was greatly reduced (Figure 6A). Western blotting revealed an overall increase in
levels of YAP on FRMD4A knockdown (Figure 6B). The in vitro observations were
confirmed in vivo: tumours in which FRMD4A expression was knocked down had increased
nuclear YAP and reduced levels of LATS when compared with control tumours (EV)
(Figure 6C and data not shown). In HNSCC the most highly differentiated tumours had the
highest proportion of nuclear YAP1 (Figure 6B).
Modulating FRMD4A and the Hippo pathway to inhibit the growth of SCCs
Having established that FRMD4A levels regulate the Hippo pathway, we next investigated
whether treatment of SCC cells with the CD44 ligand hyaluronan (HA) (23) had any effect
on the subcellular localisation of FRMD4A. When SCC13 cells were seeded on culture
dishes that had been pre-coated with HA there was a reduction in colony forming efficiency,
colony area and overall growth rate (Figure 7A). This correlated with a dramatic loss of
nuclear FRMD4A staining, increased CD44 labelling of apical cell surface microvilli and an
increase in nuclear YAP (Figure 7B).
To test whether HA may have a potential role as a therapeutic agent in vivo, mice were
xenografted with SCC13 into their back skin. Tumours were injected weekly with HA or
PBS and tumour size was measured using a Xenogen IVIS. HA injected primary tumours
were smaller than control tumours injected with PBS (Figure 7C) and there was also a
reduction in total metastatic disease quantitated as a decrease in the combined luciferase
signal from liver and lungs (Figure 7C).
Recent preclinical and clinical trials of HSP90 inhibitors have shown varying efficacy in the
treatment of several cancer types and it has been suggested that they act by depletion of
LATS1/2 in the Hippo pathway, thereby increasing nuclear YAP (24). Following injection
of SCC13 cells into the tongue, NSG mice received weekly intraperitoneal injections of the
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HSP90 inhibitor 17-DMAG (Alvespimycin) or vehicle control. 17-DMAG treated mice
showed a reduction in growth of the primary tumours and decreased metastatic disease
compared to controls (Figure 7C). 17-DMAG-treated tumours not only showed increased
nuclear YAP but also a striking loss of nuclear FRMD4A (Figure 7D).
Discussion
We originally identified FRMD4A through gene expression profiling of single human
epidermal stem cells (8) and selected it for further analysis because it was consistently
upregulated in human SCC cell lines (5). By raising antibodies to the protein we have now
shown that in human epidermis FRMD4A is only expressed in the basal cell layer, where the
stem cells reside. In contrast, FRMD4A is upregulated in HNSCC, regardless of
differentiation status, and high levels correlate with poor prognosis. Our functional studies
place FRMD4A downstream of CD44 in the Hippo pathway and suggest that targeting
FRMD4A is an effective treatment for skin and oral SCC.
FERM domains act as adaptors or scaffolds that interact with multiple protein partners (20).
The reduction in E-cadherin-mediated adhesion that occurs on FRMD4A knockdown is
consistent with the observation that FRMD4A regulates assembly of adherens junctions (9)
and is also in keeping with the role of the ERM proteins in epithelial membrane organisation
(20). FRMD4A differs from ERM proteins (20) in having potential nuclear localisation and
nuclear export sequences (NetNES 1.1 prediction software; 25) and a leucine zipper motif
(amino acids 27 to 48; 13). In support of the sequence predictions, we detected FRMD4A
not only in the cytoplasm and at cell-cell borders but also in the nucleus. If, like ERM
proteins, FRMD4A activity is regulated by phosphorylation-dependent interaction between
the FERM domain and the C-terminus (20), unfolding could potentially reveal the NLS and
leucine zipper motifs, allowing both nuclear translocation and homo- or hetero-dimerisation.
CD44 ligation with HA resulted in loss of nuclear FRMD4A, indicating that transmembrane
receptor signalling regulates FRMD4A localisation. In addition, FRMD4A binding to
cytohesin-1 and Par-3 is required for its membrane association (9). Whether there is a direct
functional interconnection between FRMD4A, CD44 and Hippo signalling, for example
involving binding of FRMD4A to the CD44 cytoplasmic domain, remains to be
investigated. In addition, the dependence of E-cadherin-mediated intercellular adhesion on
FRMD4A suggests that FRMD4A may affect multiple signalling pathways and protein
complexes.
Our in vivo studies not only indicate that targeting FRMD4A is a promising new approach
for treating SCC, but also suggest possible therapeutic options, such as HSP90 drugs (24,
26) and injection of HA (27). Whereas multiple alternatively spliced forms of CD44 are
expressed in SCC (23, 28), HA is consistently downregulated (29), suggesting that much of
the CD44 on the surface of tumour cells is unligated. HSP90 inhibitors and HA could
potentially be beneficial in HNSCC patients, either where further management by surgery or
adjuvant therapies is not possible, or concurrently with standard treatment modalities.
A case can also be made for directly targeting FRMD4A, as this would potentially be more
effective and specific than targeting upstream or downstream components in the signalling
cascade. Two other FERM domain-containing proteins, focal adhesion kinase (FAK) and
proline-rich tyrosine kinase 2 (Pyk2), have long been of interest as potential therapeutic
targets in cancer (30). In the past the focus has been on inhibiting their tyrosine kinase
activity, but targeting the FAK FERM domain blocks phosphorylation of the activation loop
(31). There is growing evidence that targeting protein-protein interactions is achievable (32)
and compounds that target the Pyk2 FERM domain have been reported (30).
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We observed a striking reciprocal relationship between nuclear accumulation of FRMD4A
and YAP, both in cultured cells and in tumours, and in those contexts increased nuclear
YAP correlated with reduced growth and increased differentiation. This is unexpected, since
the Hippo pathway is upregulated in many solid tumours (21), and YAP positively regulates
proliferation of epidermal stem cells (33, 34). In trying to reconcile these differing
observations it is worth noting that Hippo signalling is not simply a growth regulator (35).
Its role as a cell density sensor may be particularly important in the context of multilayered
epithelia (33). In mice, epidermal deletion of MST1/2 or LATS1/2 does not phenocopy
YAP1 deletion, indicating that epidermal YAP functions independently of the canonical
Hippo pathway. Instead, YAP1 forms a complex with α-catenin and 14-3-3 protein (33).
Given the effect of FRMD4A knockdown on E-cadherin containing adherens junctions, it is
tempting to speculate that FRMD4A may also impact on non-canonical Hippo signalling.
One final issue of interest is whether FRMD4A, a marker of normal epidermal stem cells
(8), is also a cancer stem cell marker. FRMD4A is upregulated in HNSCC and knockdown
stimulates terminal differentiation. It is widely expressed by cells throughout the tumour
mass, and while this could potentially reflect expansion of stem cells bearing oncogenic
mutations, it is surprising that it does not correlate with differentiation status. The same has
been observed for another marker of normal epidermal stem cells, the β1 integrin subunit
(3). Thus, rather than defining specific subsets of tumour cells, two stem cell markers,
FRMD4A and β1 integrin, show a generalised upregulation in HNSCC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. FRMD4A is expressed in basal cells of human epidermis and upregulated in HNSCC
(A) In situ hybridisation of FRMD4A and β-actin in neonatal human foreskin. Dark and
bright field images of the same sections are shown. (B) Q-PCR of transglutaminase1 and
FRMD4A mRNA levels (relative to 18S mRNA) in different layers of adult human
epidermis obtained by laser capture microdissection (left hand panels) and in cultured
human keratinocytes treated with the differentiation inducing agents shown (right hand
panels). Data are means ± SEM of 3 technical replicates (laser capture) or triplicate samples
(cultured cells). (C) Detection of FRMD4A protein. Predicted domain structure of FRMD4A
protein and location of SGO-3, 4 antibody epitopes. Western blots were probed for
FRMD4A (SGO-3) or GAPDH (loading control). WT: control SCC13; SCR: SCC13
transduced with scrambled control shRNA; B9, A7, A8, A9, A10: independent shRNAs to
FRMD4A; EK: epidermal keratinocytes; OK: oral keratinocytes. Molecular mass markers
(kDa) are indicated. Sections of human abdominal skin and human tongue squamous cell
carcinoma were labelled with antibodies to FRMD4A (green; SGO-4) and α6 integrin (red)
with DAPI nuclear counterstain. Scale bars: 50μm. (D) Kaplan Meier plots from two
independent datasets (LHS: ref 10; RHS: ref 11). Blue indicates low and green represents
high FRMD4A expression. The number of tumours in each group is given in brackets. The
optimum cut-point was determined using the method of Camp et al. (12).
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Figure 2. Effect of FRMD4A knockdown on human SCC cells in culture
Control cells (WT) were compared with cells transduced with scrambled shRNA (scr) and
FRMD4A shRNAs. (A) SCC13 cells labelled with anti-FRMD4A (green) and E-cadherin
(red) with DAPI nuclear counterstain (blue). Residual nuclear staining for FRMD4A
following knockdown is non-specific. Scale bars: 20μm. (B) Clonal growth of SCC13 and
SCC25 cells. Representative dishes stained with Rhodanile B to reveal individual clones are
shown. Data are means ± SEM of triplicate dishes. FRMD4A significantly inhibited colony
forming efficiency (P < 0.01). (C) Growth curves of SCC13 and SCC25. (D) SCC13
Matrigel invasion and sphere formation. Luciferase activity in representative wells of the
invasion assay are shown (left hand panel) and quantitated (middle panel). Right hand panel
shows % cells that formed spheres in suspension. Data are means ± SEM of triplicate dishes.
FRMD4A knockdown significantly reduced Matrigel invasion and sphere formation (P <
0.001).
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Figure 3. Primary tumours and metastases formed by orthotopic xenografts in NSG mice
(A) Luciferase/YFP lentiviral vector used to transduce cells. PL: 26 amino acid peptide
linker; pA: polyadenylation sequence. (B) Macroscopic appearance of tumours. SCC13
tumour on back (left hand panel). Luciferase activity in primary SCC13 tumour on back
(second from left) and SCC25 tumour in oral cavity (second from right) and in metastases to
lungs and liver (right hand panels). (C) Primary tumours labelled with anti-GFP, which
cross-reacts with YFP (brown) and haematoxylin. SCC13 and SCC25 tumours in back skin
and tongue are shown. Scale bars: 250μm (upper panels), 50μm (lower panels).
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Figure 4. Knockdown of FRMD4A reduces growth and metastasis of SCC in vivo
(A) Tumour growth and survival rates of mice with tongue xenografts. (B) Tumour growth
and survival rates of SCC13 dorsal skin xenografts. Left hand panel: Day 0 is first scan (14
days after grafting). Mice were switched to diet of mash containing doxycycline on day 8
after first scan. Right hand panel: Day 0 is day of grafting. (C) Lung tumours formed 10
days after tail vein injection of SCC13. Quantitation of luciferase activity is shown. (D)
Quantitation of metastatic disease in lungs and livers of mice xenografted with inducible
SCC13. Luciferase measurements were made of isolated organs at end-point of experiments
shown in (B). Data are means ± SEM of triplicate mice. *P < 0.05. (A, C) Control cells
(WT) were compared with cells transduced with scrambled shRNA (SCR) and FRMD4A
shRNA (A7). (B, D). Control cells transduced with empty lentiviral vector (EV) were
compared with cells with doxycyline-inducible FRMD4A knockdown (FRMD4A).
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Figure 5. Knockdown of FRMD4A reduces proliferation, induces apoptosis and stimulates
differentiation of SCC13 back skin xenografts
Cells were either transduced with FRMD4A shRNA (FRMD4A) or empty vector control
(EV). (A) Ki67 labelling and tumour histology. Data are means ± SEM of single sections
from three independent tumours. *P < 0.05. Haematoxylin and eosin staining shows areas of
keratinisation (pink), indicating that tumour is well differentiated. (B) Cleaved caspase-3
(brown) with haematoxylin counterstain. (C) E-cadherin labelling (brown) with
haematoxylin counterstain. (D) FRMD4A (green) and involucrin (red) labelling with DAPI
nuclear counterstain (blue). Scale bars: 50μm (H&E staining in A), 20μm (all other panels).
Goldie et al. Page 17
Cancer Res. Author manuscript; available in PMC 2013 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 6. FRMD4A regulates the HIPPO pathway
(A) Untransduced (WT), FRMD4A shRNA (A7) or scrambled shRNA (SCR) transduced
SCC13 cells were labelled with antibodies to FRMD4A (green, left hand panels) and YAP1
(red, middle panels) or LATS1 (green, right hand panels) and MST1 (red, right hand panels)
and counterstained with DAPI (blue). Left hand and middle panels are each show same
field. (B) Western blot probed for YAP1 and GAPDH (loading control) and quantitation of
average % cells with nuclear or cytoplasmic YAP1 in human oral SCCs of differing
differentiation status (n=4 for each tumour type). (C) SCC13 back skin xenografts labelled
for LATS1 (green) and YAP1 (red) with DAPI nuclear counterstain (blue). Cells were
transduced with empty lentiviral vector (EV) or doxycycline-inducible FRMD4A shRNA.
Scale bars: 10μm (A), 20μm (C).
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Figure 7. Modulating FRMD4A and HIPPO via HA or 17-DMAG reduces SCC growth in vitro
and in xenografts
(A) SCC13 cells grown at clonal density on culture dishes coated with PBS or HA.
Representative dishes stained with rhodanile blue are shown. % colony formation, colony
area and colony staining intensity (readout of cell density per unit colony area) were
quantitated Data are means ± SEM of triplicate dishes. (B) SCC13 cells grown on coverslips
coated with PBS or HA and labelled with antibodies to FRMD4A (green) and CD44 (red),
or YAP1 (red). Left hand and second from left panels are pairs of images showing same
fields. (C) Effect of HA or 17-DMAG treatment on primary tumour growth (SCC13 in the
case of HA; SCC25 in the case of 17-DMAG) and total metastatic disease (combined values
for liver and lungs) in tongue xenografts. Quantitative data are means ± SEM (n=5). (D)
Sections of primary tumours were labelled with antibodies to FRMD4A (green) or YAP1
(red). Scale bars: 10μm (B), 20μm (D).
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